TVTX
Travere Therapeutics Inc
NASDAQ: TVTX · HEALTHCARE · BIOTECHNOLOGY
$40.10
-1.93% today
Updated 2026-04-29
Market cap
$3.70B
P/E ratio
—
P/S ratio
7.55x
EPS (TTM)
$-0.57
Dividend yield
—
52W range
$14 – $43
Volume
1.9M
Travere Therapeutics Inc (TVTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $28.20M | $99.89M | $133.59M | $154.94M | $164.25M | $175.34M | $198.32M | $131.84M | $109.46M | $145.24M | $233.18M | $490.73M |
| Revenue growth (YoY) | — | — | — | — | — | +254.2% | +33.7% | +16.0% | +6.0% | +6.8% | +13.1% | -33.5% | -17.0% | +32.7% | +60.5% | +110.5% |
| Cost of revenue | — | — | — | — | $570979.00 | $2.19M | $4.55M | $3.60M | $5.53M | $5.23M | $6.13M | $3.82M | $4.42M | $11.45M | $7.74M | $71.08M |
| Gross profit | — | — | — | — | $27.63M | $97.71M | $129.04M | $151.33M | $158.72M | $170.10M | $192.19M | $128.02M | $105.04M | $133.79M | $225.43M | $419.65M |
| Gross margin | — | — | — | — | 98.0% | 97.8% | 96.6% | 97.7% | 96.6% | 97.0% | 96.9% | 97.1% | 96.0% | 92.1% | 96.7% | 85.5% |
| R&D | — | — | $662502.00 | $7.08M | $47.80M | $50.43M | $70.85M | $78.17M | $123.76M | $140.96M | $131.77M | $201.16M | $227.33M | $244.99M | $282.70M | $206.01M |
| SG&A | $13432.00 | $12825.00 | $30.26M | $16.89M | $59.64M | $79.54M | $98.02M | $103.96M | $103.65M | $128.95M | $135.80M | $126.28M | $197.52M | $265.54M | $264.12M | $337.20M |
| Operating income | $-18266.00 | $-12825.00 | $-30.24M | $-23.97M | $-79.81M | $-50.75M | $-58.21M | $-53.79M | $-80.04M | $-99.81M | $-176.16M | $-199.43M | $-319.81M | $-388.14M | $-323.83M | $-62.82M |
| Operating margin | — | — | — | — | -283.0% | -50.8% | -43.6% | -34.7% | -48.7% | -56.9% | -88.8% | -151.3% | -292.2% | -267.2% | -138.9% | -12.8% |
| EBITDA | $-18266.00 | $-12825.00 | $-30.11M | $-14.03M | $-74.11M | $129.46M | $-38.79M | $-38.67M | $-73.39M | $-107.21M | $-145.16M | $-184.46M | $-299.42M | $-326.25M | $-265.77M | $22.22M |
| EBITDA margin | — | — | — | — | -262.8% | 129.6% | -29.0% | -25.0% | -44.7% | -61.1% | -73.2% | -139.9% | -273.5% | -224.6% | -114.0% | 4.5% |
| EBIT | $-18266.00 | $-12825.00 | $-30.24M | $-14.24M | $-79.51M | $116.06M | $-54.92M | $-56.48M | $-92.06M | $-127.62M | $-169.74M | $-197.20M | $-320.14M | $-364.78M | $-309.33M | $-38.52M |
| Interest expense | $10333.00 | $2000.00 | $105917.00 | $19.50M | $55.02M | $19.50M | $4.73M | $4.42M | $9.81M | $18.83M | $19.05M | $19.68M | $11.01M | $11.33M | $11.18M | $10.75M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-18266.00 | $-14825.00 | $-30.34M | $-33.82M | $-110.94M | $117.24M | $-47.90M | $-59.73M | $-102.68M | $-146.43M | $-169.43M | $-180.09M | $-278.48M | $-111.40M | $-321.55M | $-50.26M |
| Net income growth (YoY) | — | +18.8% | -204580.3% | -11.5% | -228.0% | +205.7% | -140.9% | -24.7% | -71.9% | -42.6% | -15.7% | -6.3% | -54.6% | +60.0% | -188.6% | +84.4% |
| Profit margin | — | — | — | — | -393.4% | 117.4% | -35.9% | -38.6% | -62.5% | -83.5% | -85.4% | -136.6% | -254.4% | -76.7% | -137.9% | -10.2% |